Dr. Douglas Sheeley

About Dr. Douglas Sheeley

Doug, a biochemist with a background in technology development, co-leads the Biomedical Technology Research Resources (BTRRs) program and serves as the program director for the Models of Infectious Disease Agent Study (MIDAS) program. He also is the project team leader for the NIH Common Fund Technology Centers for Networks and Pathways program.

Funding Opportunities to Develop Glycoscience Tools and Technologies

NIGMS and the National Institute of Dental and Craniofacial Research are leading the new NIH Common Fund glycoscience program that is focused on the development of accessible and affordable tools and technologies for studying carbohydrates and their functions. The overall objective is to enable researchers in all biomedical fields to dramatically advance understanding of the roles of these complex molecules in health and disease.

The NIH Common Fund recently issued four funding opportunity announcements from this program:

The application deadline for each announcement is December 10, with optional letters of intent due by November 10. For more information about the glycoscience program, view the technical assistance Webinar or contact either one of us at sheeleyd@mail.nih.gov or marinop@nigms.nih.gov.

Give Input on Structural Biology Resource and Infrastructure Needs

Earlier this year, I told you about the formation of two committees focused on Protein Structure Initiative (PSI) transition planning. These committees are charged with determining what unique resources and capabilities developed during the PSI should be preserved after the initiative ends and how this preservation should be done.

An important part of this process is getting input from the community, so we have just issued a request for information (RFI), NOT-GM-14-115, seeking comments about structural biology resources that have a high impact on the community, whether those resources have been supported through the PSI or by other means. We also want to hear what you think about the future of structural biology-related technology development, which has been an important feature of the PSI.

While the RFI invites comments on these specific topics, you should not feel limited to them—we welcome any comments that you feel are relevant.

To respond to the RFI, send an e-mail to nigmspsirfi@mail.nih.gov by May 23, 2014. When we compile the responses, we’ll remove any personal identifiers like names and e-mail addresses and only use de-identified comments.

If you have any questions about the RFI or the transition committees, please let me know.

Protein Structure Initiative Transition Planning Committees

Shortly after NIGMS Director Jon Lorsch announced plans to sunset the Protein Structure Initiative after the completion of the PSI:Biology phase in 2015, he commissioned two committees to determine what unique resources and capabilities developed during the PSI should be preserved and how that should be done. The committees, which are working together, held their first meetings in December and expect to present their recommendations within the year.

The external committee, which includes practitioners of structural biology and biomedical researchers who use structural biology data and resources in their work, will primarily focus on community needs. It also will suggest emerging challenges and opportunities in structural biology.

The internal committee, which is composed of NIH staff, will focus on how to implement the priorities identified by the external committee. The group includes a member from each NIGMS scientific division as well as several representatives from other NIH institutes who have experience managing structural biology and large, complex research programs.

The work of these committees will help define how we can provide continued access to important structural biology resources and identify new directions for technology development with potential for broad biomedical impact.

As Jon wrote in a Feedback Loop post about bolstering support for investigator-initiated research and as also reported in a Nature news article Exit icon, the decision to sunset a large set-aside program that has received substantial investments, such as the PSI, should not be interpreted as a lack of support for team science. Multidisciplinary collaborations are likely to become increasingly important as we delve deeper into complex biological problems, and we will continue to sponsor team approaches to biomedical research. We also remain committed to supporting structural biology research through investigator-initiated grant mechanisms, innovative technology development and access to critical resources.